GlassScriptPhysician profile
Sopalla Dul
NPI 1205364817
$2,013.52
in general payments reported to CMS, 2019-2025
16 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $525 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989 · Education: $24.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.35 |
| Education | $24.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $368.58 | 2025 | |
| Lantheus Medical Imaging, INC. | $278.83 | 2023 | Definity |
| Inari Medical, INC. | $246.13 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Ucb, INC. | $203.01 | 2025 | Bimzelx |
| Pfizer INC. | $189.73 | 2025 | |
| Abbvie INC. | $139.20 | 2025 | |
| Janssen Biotech, INC. | $138.51 | 2025 | Tremfya, Stelara, Simponi |
| Leo Pharma INC. | $105.12 | 2025 | Adbry |
| Amgen INC. | $93.91 | 2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $80.41 | 2025 | |
| Biofrontera INC. | $45.92 | 2025 | Rhodoled Xl, Ameluz, Bf-Rhodoled |
| Galderma Laboratories, L.P. | $35.06 | 2025 | Nemluvio |
| Lilly USA, LLC | $32.38 | 2025 | Ebglyss, Taltz |
| Organon LLC | $26.34 | 2025 | |
| Incyte Corporation | $15.91 | 2025 | Opzelura |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $14.48 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sopalla Dul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.